Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2020)

Monopar Therapeutics' Change in Accured Expenses history spans 4 years, with the latest figure at $636970.0 for Q4 2020.

  • For Q4 2020, Change in Accured Expenses rose 109.37% year-over-year to $636970.0; the TTM value through Dec 2020 reached $447598.0, up 83.79%, while the annual FY2024 figure was $506791.0, 138.0% up from the prior year.
  • Change in Accured Expenses for Q4 2020 was $636970.0 at Monopar Therapeutics, up from -$21418.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $636970.0 in Q4 2020 and bottomed at -$331106.0 in Q1 2020.
  • The 4-year median for Change in Accured Expenses is $43201.5 (2017), against an average of $64135.8.
  • The largest YoY upside for Change in Accured Expenses was 889.15% in 2019 against a maximum downside of 1050.57% in 2019.
  • A 4-year view of Change in Accured Expenses shows it stood at -$26070.0 in 2017, then skyrocketed by 436.24% to $87658.0 in 2018, then skyrocketed by 247.06% to $304229.0 in 2019, then surged by 109.37% to $636970.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Change in Accured Expenses are $636970.0 (Q4 2020), -$21418.0 (Q3 2020), and $163152.0 (Q2 2020).